# **HINOON**

#### CY21 Result Review: BUY Stance Maintained



Equity Research | Pharmaceuticals | Wednesday, 16 March, 2022

HINOON has announced its CY21 result where it posted a profit after tax of Rs1.808bn (EPS: Rs47.48) as compared to profit after tax of Rs1.421bn (EPS: Rs37.31) in the same period last year, up by 27.3% YoY.


The company has posted a revenue of Rs13.001bn against Rs10.698bn in SPLY, recording a growth of 21.5% YoY. We note that this growth is attributed to the increase in volumetric sales. The gross margin has been elevated slightly to 49.3% as compared to 47.9% during SPLY.

SG&A expenses have been increased by 27.6% to Rs3.95bn as compared to Rs3.1bn during SPLY. Lastly, the effective taxation has been decreased to 23.8% as compared to 26.1% during SPLY.

HINOON is currently trading at CY22E PE of 10.9x. Furthermore, it is also trading at a CY22E PB of 3.44x which offers a discount of 36% relative to its historical 3-year average of 5.39x. We maintain our **BUY** stance on the script with a DCF based Dec-22 TP of Rs800 which provides an upside potential of 31%. Further, the scrip provides a dividend yield of 3.85%, which makes the cumulative return of 35%.

Rupees' millions	4QCY21	4QCY20	YoY	CY21	CY20	Yo
Net Sales	3,421	2,798	22.3% ▲	13,001	10,698	21.5%
Cost of Sales	1,755	1,530	14.7% ▲	6,585	5,576	18.1%
Gross Profit	1,666	1,268	31.4% ▲	6,416	5,121	25.3% 🛦
SG&A Expenses	946	680	39.2% ▲	3,947	3,094	27.6%
Other Expenses	66	54	21.0% 🛦	214	179	19.6%
Operating Profit	653	533	22.5% ▲	2,245	1,842	21.9%
Other Income	39	44	11.2% ▼	154	104	48.2%
Finance Cost	10	18	44.5% ▼	27	24	11.7%
Profit Before Taxation	682	559	21.9% ▲	2,372	1,922	23.4%
Taxation	101	117	13.1% ▼	564	501	12.6%
Profit After Taxation	581	443	31.2% ▲	1,808	1,421	27.3%
Earnings Per Share	15.26	11.63	31.2% ▲	47.48	37.31	27.3%
Dividend	20.00	15.00		20.00	15.00	
Bonus	0%	10%		0.00	0.10	
	Closing	period : April 1	1, 2022 – April :	18, 2022		
Gross Margin	48.7%	45.3%	3.4% ▲	49.3%	47.9%	1.5%
SG&A Expenses to Sales	27.7%	24.3%	3.4% ▲	30.4%	28.9%	1.4%
Other Expenses to Sales	1.9%	1.9%	0.0% ▼	1.6%	1.7%	0.0%
Other Income to Sales	1.2%	1.6%	0.4% ▼	1.2%	1.0%	0.2%
Effective Taxation	14.8%	20.8%	6.0% ▼	23.8%	26.1%	2.3%
Net Margin	17.0%	15.8%	1.2% ▲	13.9%	13.3%	0.6%

Source: ACPL Research, Company Financials



## **Financial Projections**

Rupees' millions	CY19A	CY20A	CY21A	CY22E	CY23E	CY24E	CY25E
Net sales	9,048	10,698	13,001	14,920	16,412	18,053	19,859
Cost of sale	4,886	5,576	6,585	7,557	8,313	9,144	10,059
Gross profit	4,162	5,121	6,416	7,363	8,099	8,909	9,800
Selling and distribution	2,387	2,645	3,416	3,921	4,313	4,744	5,218
Administration expenses	370	448	531	609	670	737	811
Research and development	5	6	9	10	11	12	13
Other operating expenses	120	179	214	179	197	217	238
Operating Profit	1,280	1,842	2,245	2,644	2,908	3,199	3,519
Other operating income	85	104	154	176	194	213	235
Finance cost	24	24	27	20	20	20	20
Profit before taxation	1,341	1,922	2,372	2,800	3,082	3,392	3,734
Taxation	370	501	564	666	733	807	888
Profit after taxation	971	1,421	1,808	2,134	2,349	2,586	2,846
EPS	25.50	37.31	47.48	56.05	61.70	67.91	74.74

Source: ACPL Research, Company Financials

### **Horizontal Analysis**

	CY19A	CY20A	CY21A	CY22E	CY23E	CY24E	CY25E
Net sales	25.7%	20.6%	18.2%	21.5%	14.8%	10.0%	10.0%
Cost of sale	28.1%	22.1%	14.1%	18.1%	14.8%	10.0%	10.0%
Gross profit	23.0%	18.9%	23.1%	25.3%	14.8%	10.0%	10.0%
Selling and distribution	26.7%	17.8%	10.8%	29.1%	14.8%	10.0%	10.0%
Administration expenses	29.5%	5.8%	21.2%	18.5%	14.8%	10.0%	10.0%
Research and development	5.3%	31.9%	27.2%	36.0%	14.8%	10.0%	10.0%
Other operating expenses	4.9%	35.6%	49.0%	19.6%	-16.4%	10.0%	10.0%
Operating Profit	16.2%	24.1%	43.9%	21.9%	17.7%	10.0%	10.0%
Other operating income	12.9%	157.9%	21.7%	48.2%	14.8%	10.0%	10.0%
Finance cost	69.1%	185.2%	0.8%	11.7%	-25.8%	0.0%	0.0%
Profit before taxation	15.8%	27.0%	43.3%	23.4%	18.0%	10.1%	10.1%
Taxation	15.6%	12.0%	35.4%	12.6%	18.0%	10.1%	10.1%
Profit after taxation	15.9%	33.8%	46.3%	27.3%	18.0%	10.1%	10.1%
EPS	15.9%	33.8%	46.3%	27.3%	18.0%	10.1%	10.1%

Source: ACPL Research, Company Financials

Abbasi and Company (Pvt.) Ltd.

## **Key Ratios**

Profitability Ratios		CY19A	CY20A	CY21A	CY22E	CY23E	CY24E	CY25E
GP Margin	%	46.00	47.87	49.35	49.35	49.35	49.35	49.35
NP Margin	%	10.73	13.28	13.91	14.30	14.31	14.32	14.33
OP Margin	%	14.14	17.22	17.27	17.72	17.72	17.72	17.72
ROE	%	28.21	31.67	32.79	31.60	28.96	26.90	25.27
ROCE	%	24.59	26.59	29.14	28.67	26.68	25.09	23.81
ROA	%	20.98	22.09	20.06	16.96	14.63	13.01	11.82
Liquidity Ratios		CY19A	CY20A	CY21A	CY22E	CY23E	CY24E	CY25E
Current	х	4.76	4.30	5.25	5.51	6.75	7.95	9.13
Acid-test	х	3.21	3.24	3.03	2.12	2.12	2.12	2.13
Cash to current liab.	х	1.26	0.76	2.01	3.24	4.47	5.68	6.84
Activity Ratios		CY19A	CY20A	CY21A	CY22E	CY23E	CY24E	CY25E
Inventory Turnover	х	3	3	3	3	3	3	3
Inventory Days		117	128	125	118	115	115	115
Receivables Days		17	12	17	11	10	10	10
Payables Days		45	45	45	65	65	65	65
Operating Cycle		90	95	98	64	60	60	60
Investment Ratios		CY19A	CY20A	CY21A	CY22E	CY23E	CY24E	CY25E
EPS		25.50	37.31	47.48	56.05	61.70	67.91	74.74
DPS		13.00	15.00	20.00	23.50	26.00	28.50	31.50
Div. Yield	%	2.13	2.45	3.27	3.85	4.26	4.66	5.16
Dividend Cover	х	1.96	2.49	2.37	2.39	2.37	2.38	2.37
BVPS		90.39	117.82	144.81	177.36	213.06	252.46	295.70
Payout	%	50.98	40.20	42.12	41.93	42.14	41.97	42.15
Retention	%	49.02	59.80	57.88	58.07	57.86	58.03	57.85
No. of Shares	'000	38,076	38,076	38,076	38,076	38,076	38,076	38,076
P/E		23.96	16.38	12.87	10.90	9.90	9.00	8.18
Sales per share		237.62	280.95	341.44	391.85	431.03	474.13	521.55
P/BV		6.76	5.19	4.22	3.44	2.87	2.42	2.07
Price to Sales		3.38	2.86	2.35	2.05	1.86	1.69	1.54
Gearing Ratios		CY19A	CY20A	CY21A	CY22E	CY23E	CY24E	CY25E
Debt to Equity	х	0.02	0.11	0.06	0.05	0.04	0.03	0.03
Interest Cover	х	53.50	76.41	83.37	132.34	145.58	160.14	176.15

Source: ACPL Research, Company Financials

Abbasi and Company (Pvt.) Ltd.

This report has been prepared by Abbasi & Company (Private) Limited and is provided for information purposes only. Under no circumstances, this is to be used or considered as an offer to sell or solicitation of any offer to buy. While reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. From time to time, Abbasi & Company (Private) Limited and or any of its officers or directors may, as permitted by applicable laws, have a position, or otherwise be interested in any transaction, in any securities directly or indirectly subject of this report. This report is provided only for the information of professional advisers who are expected to make their own investment decisions without undue reliance on this report. Investments in capital markets are subject to market risk and Abbasi & Company (Private) Limited accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. In particular, the report takes no account of the investment objectives, financial situation and needs of investors, who should seek further professional advice or rely upon their own judgment and acumen before making any investment. The views expressed in this report are those of Abbasi & Company (Private) Limited Research Department and do not necessarily reflect those of the company or its directors. Abbasi & Company (Private) Limited as a firm may have business relationships, including investment--banking relationships, with the companies referred to in this report. Abbasi & Company (Private) Limited does not act as a market maker in the securities of the subject company. Abbasi & Company (Private) Limited or any officers, directors, associates or close relatives do not have a financial interest in the securities of the subject company to an amount exceeding 1% of the value of the securities of the subject company at the time of issuance of this report. Abbasi & Company (Private) Limited or any officers, directors, associates or close relatives are not currently serving or have served in the past three years as a director or officer of the subject company. Abbasi & Company (Private) Limited or any officers, directors, associates or close relatives have not received compensation from the subject company in the previous 12 months. The subject company currently is not, or during the 12-month period preceding the date of publication or distribution of this report, was not, a client of Abbasi & Company (Private) Limited. We have not managed or co-managed a public offering or any take-over, buyback or delisting offer of securities for the subject company in the past 12 months and/or received compensation for corporate advisory services, brokerage services or underwriting services from the subject company in the past 12 months. Abbasi & Company (Private) Limited does not expect to receive or intend to seek compensation for corporate advisory services or underwriting services from the subject company in the next 3 months

All rights reserved by Abbasi & Company (Private) Limited. This report or any portion hereof may not be reproduced, distributed or published by any person for any purpose whatsoever. Nor can it be sent to a third party without prior consent of Abbasi & Company (Private) Limited. Action could be taken for unauthorized reproduction, distribution or publication

#### **VALIDITY OF THE PUBLICATION OR REPORT**

The information in this publication or report is, regardless of source, given in good faith, and may only be valid as of the stated date of this publication or report. The information may be subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company, jurisdiction or financial instruments referred to in this report. The valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report and were based upon several estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein is not to be relied upon as a representation and/or warranty by Abbasi & Company (Private) Limited and/or its other associated and affiliated companies, that:

- . Such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- II. There is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein

#### **DEFINITION OF TERMS**

TP	Target Price	CAGR	Compound Annual Growth Rate	FCF	Free Cash Flows
FCFE	Free Cash Flows to Equity	FCFF	Free Cash Flows to Firm	DCF	Discounted Cash Flows
PE	Price to Earnings Ratio	PB	Price to Book Ratio	BVPS	Book Value Per Share
EPS	Earnings Per Share	DPS	Dividend Per Share	ROE	Return of Equity
ROA	Return on Assets	SOTP	Sum of the Parts	LDCP	Last Day Closing Price

#### **VALUATION METHODOLOGY**

To arrive at our Target Price, Abbasi & Company (Private) Limited uses different valuation methods which include:

- I. Discounted Cash Flow Model
- II. Dividend Discount Model
- III. Relative Valuation Model
- IV. Sum of Parts Valuation

#### RATINGS CRITERIA

Abbasi & Company (Private) Limited employs a three-tier ratings system to rate a stock and sector, as mentioned below, which is based upon the level of expected return for a specific stock and outlook of sector. The rating is based on the following with stated time horizon

Stock Rating	Expected Total Return
BUY	Greater than 15%
HOLD	Between -5% to 15%
SELL	Less than and equal to -5%

Sector Rating	Sector Outlook
Overweight	Positive
Market Weight	Neutral
Underweight	Negative

Ratings are updated to account for any development impacting the economy/sector/company, changes in analysts' assumptions or a combination of these factors.

### RESEARCH DISSEMINATION POLICY

Abbasi & Company (Private) Limited endeavors to make all reasonable efforts to disseminate research to all eligible clients in a timely manner through either physical or electronic distribution such as email, fax mail etc. Nevertheless, all clients may not receive the material at the same time

#### OTHER DISCLOSURES

The research analyst is primarily involved in the preparation of this report, certifies that:

- I. The views expressed in this report accurately reflect his/her personal views about the subject company/stock /sector and economy
- II. No part of his/her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report

The Research Analyst is not and was not involved in issuing of a research report on any of the subject company's associated companies

#### RESEARCH DEPARTMENT

6 - Shadman, Lahore

Phone: (+92) 42 38302028; Ext 116, 117 Email: research@abbasiandcompany.com web: www.abbasiandcompany.com

#### **HEAD OFFICE**

6 - Shadman, Lahore Phone: (+92) 42 38302028

Email: info@abbasiandcompany.com web: www.abbasiandcompany.com

#### **BRANCH OFFICE**

42 - Mall Road, Lahore Phone: (+92) 42 37320707

Email: info@abbasiandcompany.com web: www.abbasiandcompany.com